US drug pricing pressure may delay launches in cheaper markets: analyst

An analyst argues that U.S. efforts to lower drug prices are prompting pharmaceutical companies to delay product launches in lower-income markets, potentially reducing global access. The claim is an expert opinion, not yet backed by systematic data. If true, it would signal a trade-off between U.S. pricing reforms and global health equity.